Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions.
PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood
transfusions in patients with hematologic malignancies.
Phase:
Phase 2
Details
Lead Sponsor:
Comprehensive Cancer Center of Wake Forest University Wake Forest University Health Sciences